Donna S. Zhukovsky

Dr. Donna S. Zhukovsky

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2017 in JAMA
Verified
Journal Article
Open access
PDF file
DHDavid Hui
David Hui
SFSusan Frisbee-Hume
Susan Frisbee-Hume
AWAnnie Wilson
Annie Wilson
SDSeyedeh S. Dibaj
Seyedeh S. Dibaj
TNThuc Nguyen
Thuc Nguyen
EBEduardo Bruera
Eduardo Bruera
Quiz Ref ID Delirium was found in approximately 90% of patients in the last days of life in a 2013 systematic review.1 Approximately 50% to 70% of patients with delirium have hyperactive or mixed subtypes, characterized by restlessness, agitation, or aggressive violent behavior. Agitation can be highly distressing to patients, caregivers, and health care professionals, posing a significant safety risk to those involved.2-4

1 April 2009 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
DZDonna S. Zhukovsky
Donna S. Zhukovsky
CHCynthia E. Herzog
Cynthia E. Herzog
GKGuddi Kaur
Guddi Kaur
JPJ. Lynn Palmer
J. Lynn Palmer
EBEduardo Bruera
Eduardo Bruera
Background: There are few data describing symptom prevalence in children with cancer. The available literature suggests that similar to adults, symptom prevalence and distress are high and that communication regarding end-of-life care needs is limited. Objectives: We evaluated symptom prevalence, treatment recommendations, and communication about end-of-life care issues for children seen in pediatric palliative care consultation (PCC) at one National Cancer Institute-designated comprehensive cancer center. The goal of our study was to obtain baseline data to target areas in need of intervention. Methods: A retrospective chart review was conducted of consecutive patients referred to a newly initiated PCC service. Analysis was descriptive. Results: Over the 9-month study period, 15 children were referred. Median age was 13 years (2–24), with 10 males. Eleven children were receiving chemotherapy and/or radiation. Median number of documented symptoms at PCC was 5 per child (2–10). PCC universally resulted in the detection of symptoms not identified by the primary team, for a median of 3 new symptoms per patient (0–9). Documented communication about most end-of-life care issues with parents was uncommon, and rarely involved children. Initial PPCC resulted in recommendations for medication changes in 14 of 15 children, allied health consultation in 8, counseling in 11, patient care conference in 3, and family conference in 6. For the 12 patients who died, median time from PPCC to death was 8 days (1–96). Conclusions: PCC, although late in the course, resulted in the detection of multiple symptom control and communication needs, and corresponding treatment recommendations.

28 February 1995 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
DZDonna S. Zhukovsky
Donna S. Zhukovsky
EGElizabeth Gorowski
Elizabeth Gorowski
JHJoyce Hausdorff
Joyce Hausdorff
BNBarbara Napolitano
Barbara Napolitano
MLMartin Lesser
Martin Lesser

1 December 2017 in Journal of Oncology Practice
Verified
Journal Article
Closed access
AHAli Haider
Ali Haider
DZDonna S. Zhukovsky
Donna S. Zhukovsky
YMYee Choon Meng
Yee Choon Meng
JBJoseph Baidoo
Joseph Baidoo
KTKimberson C. Tanco
Kimberson C. Tanco
Eduardo BrueraEduardo Bruera
Eduardo Bruera
Introduction: In the United States, opioid regulations have become increasingly stringent in recent years. Increased regulatory scrutiny, in part, is related to heightened awareness through literature and a recent media blitz on the opioid prescription epidemic. These regulations have the potential to impact prescription trends by health care providers. Our objective was to evaluate changes in the type and dose of opioid prescriptions among patients who are referred by oncologists to an outpatient palliative care clinic.Materials and Methods: We reviewed the electronic health records of 750 patients who were seen as new consultations at MD Anderson Cancer Center’s outpatient palliative care clinic between January 1 and April 30 each year from 2010 through 2015. Data collected included demographics, cancer type and stage, symptom assessment, performance status, opioid type, and opioid dose defined as the morphine equivalent daily dose (MEDD).Results: Median age was 59 years (interquartile range [IQR], 51 to 67), 383 (51%) were female, 529 (70%) were white, and 654 (87%)of patients had advanced cancer. In 2010, median MEDD before referral was 78 mg/d (IQR, 30 to 150); however, by 2015, the MEDD had progressively decreased to 40 mg/d (IQR, 19 to 80; P = .001). Hydrocodone was the most common opioid prescribed between 2010 and 2015; however, after its reclassification as a schedule II opioid in October 2014, the use of tramadol, a schedule IV opioid, increased ( P < .001).Conclusion: During the past several years, the MEDD prescribed by referring oncologists has decreased. After hydrocodone reclassification, the use of tramadol with less stringent prescription limits has increased.

28 July 2015 in Cancer
Verified
Journal Article
Open access
PDF file
DZDonna S. Zhukovsky
Donna S. Zhukovsky
CRCathy L. Rozmus
Cathy L. Rozmus
RRRhonda S. Robert
Rhonda S. Robert
EBEduardo Bruera
Eduardo Bruera
RWRobert J. Wells
Robert J. Wells
MCMarlene Z. Cohen
Marlene Z. Cohen
BACKGROUND: Systematic symptom assessment is not routinely performed in pediatric oncology. The objectives of the current study were to characterize the symptoms of pediatric oncology outpatients and evaluate agreement between patient and proxy reports and the association between children's ratings and oncologists' treatment recommendations.METHODS: Two versions of the pediatric Memorial Symptom Assessment Scale (pMSAS) were translated into Spanish. An age‐appropriate and language‐appropriate pMSAS was administered independently before visits to the oncologist to patients and family caregivers (caregivers) and after visits to consenting oncologists. Statistical analysis included Spearman correlation coefficients and weighted kappa values.RESULTS: English and Spanish results were similar and were combined. A total of 60 children and their caregivers completed the pMSAS. The children had a median age of 10 years (range, 7‐18 years); approximately 62% were male and 33% were Spanish‐speaking. Fourteen oncologists completed the pMSAS for 25 patients. Nine patients (15%) had no symptoms and 38 patients (63%) reported ≥2 symptoms. The most common symptoms were fatigue (12 patients; 40%) and itch (9 patients; 30%) for the younger children and pain (15 patients; 50%) and lack of energy (13 patients; 45%) among the older children. Total and subscale score agreement varied by proxy type and subscale, ranging from fair to good for most comparisons. Agreement for individual symptoms between the patient and proxy ranged from a kappa of −0.30 (95% confidence interval, −0.43 to −0.01) to 0.91 (95% confidence interval, 0.75 to 1.00). Three of 51 symptomatic patients (6%) had treatment recommendations documented in the electronic health record.CONCLUSIONS: Symptoms are common and cross several functional domains. Proxy and child reports are often not congruent, possibly explaining apparent undertreatment among this group of patients. Cancer 2015;121:4080–4087. © 2015 American Cancer Society.

1 March 2003 in American Journal of Hospice and Palliative Medicine®
Verified
Journal Article
Closed access
PDF file
TGTerence Gutgsell
Terence Gutgsell
DWDeclan Walsh
Declan Walsh
DZDonna S. Zhukovsky
Donna S. Zhukovsky
FGFrancisco Gonzales
Francisco Gonzales
RLRuth Lagman
Ruth Lagman
Comprehensive pain evaluation is requisite for optimal management. Few studies have evaluated pain syndromes and adequacy of associated analgesic regimens in one population. Available studies in cancer populations have focused on ambulatory patients or hospice-type inpatients. This study was designed to evaluate multiple characteristics of pain and adequacy of therapy in a broad spectrum of patients with advanced cancer presenting to a palliative medicine service. One hundred pain patients (95 with cancer) underwent a comprehensive pain evaluation consisting of history, physical examination, review of available diagnostics, and a pain assessment tool designed for routine clinical use. Seventy-one percent of 141 evaluable patients reported pain in the month before referral. In these 100 patients, 158 distinct sites of pain were reported, with 88 percent reporting a maximum of 2. Pain due to tumor was the most common cause (68 percent), and the most common pathophysiologic mechanism, somatic (52 percent). Pain was almost equally divided between continuous (48 percent) and intermittent (52 percent). Breakthrough pain occurred in 75 percent of continuous pains. Of these, 30 percent were exclusively incidental, 26 percent nonincidental, and 16 percent due to end-of-dose failure. The remainder was of mixed etiology, but almost always with an incidental component. Of intermittent pain syndromes, 61 percent were incidental. On referral, analgesic dosing was inadequate and was compounded by use of regimens that typically did not meet peer-reviewed guidelines. Comprehensive studies rigorously evaluating characteristics of pain and response to treatment are a necessary first step toward more effective treatments for difficult pain syndromes.